Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.1470
+0.0005 (0.34%)
Sep 4, 2026, 5:29 PM CET
Prostatype Genomics AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -37.9 | -44.5 | -41.05 | -41.44 | -29.09 | -15.63 |
Depreciation & Amortization | 2.19 | 2.19 | 1.98 | 0.02 | 0.05 | 0.09 |
Other Amortization | - | - | - | 1.86 | 1.86 | - |
Other Operating Activities | 2.26 | 5.53 | -1.06 | 0.6 | 0 | - |
Change in Accounts Receivable | 0.43 | 0.26 | -0.24 | 0.98 | -1.42 | 0.13 |
Change in Inventory | 0.07 | 0.02 | 0.11 | -0.02 | - | 0.21 |
Change in Other Net Operating Assets | 12.06 | 12.7 | -4.44 | 8.86 | 0.91 | -0.88 |
Operating Cash Flow | -20.9 | -23.8 | -44.71 | -29.14 | -27.69 | -16.08 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.06 | -0.26 | -0.29 | -0.08 | - | - |
Sale (Purchase) of Intangibles | -12.2 | -13.18 | -7.58 | -8.49 | - | -2.5 |
Investment in Securities | -0.01 | 0.08 | -0.49 | -0 | - | - |
Investing Cash Flow | -12.27 | -13.36 | -8.36 | -8.57 | - | -2.5 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 10.55 | 8.83 | 16.2 | - | 23.25 |
Total Debt Issued | 11.8 | 10.55 | 8.83 | 16.2 | - | 23.25 |
Long-Term Debt Repaid | - | -5.32 | -15.23 | -5.4 | -0.4 | -0.2 |
Total Debt Repaid | -0.3 | -5.32 | -15.23 | -5.4 | -0.4 | -0.2 |
Net Debt Issued (Repaid) | 11.5 | 5.23 | -6.4 | 10.8 | -0.4 | 23.05 |
Issuance of Common Stock | 31.6 | 31.6 | 66.15 | 18.11 | 19.25 | - |
Other Financing Activities | -22.46 | 0 | - | - | - | - |
Financing Cash Flow | 20.64 | 36.83 | 59.75 | 28.91 | 18.85 | 23.05 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -0.01 | -0.02 | 0.05 | -0.01 | - | - |
Miscellaneous Cash Flow Adjustments | 0 | - | - | -0 | - | - |
Net Cash Flow | -12.54 | -0.35 | 6.74 | -8.81 | -8.84 | 4.47 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -20.96 | -24.06 | -44.99 | -29.21 | -27.69 | -16.08 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -2066.86% | -4050.34% | -2345.88% | -783.61% | -4054.61% | -640.66% |
Free Cash Flow Per Share | - | -0.71 | -31.89 | -361.46 | -1521.34 | -1137.23 |
Levered Free Cash Flow | -8.19 | -25.17 | -16.09 | -43.78 | -16.8 | -12.72 |
Unlevered Free Cash Flow | -6.98 | -24.16 | -15.04 | -42.82 | -16.55 | -12.67 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Change in Working Capital | 12.56 | 12.98 | -4.57 | 9.82 | -0.51 | -0.54 |